Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: Results of N-SAS BC 04, the TEAM Japan substudy

Oncology

Volumn 79, Issue 5-6, 2011, Pages 376-381

  Aihara, T ^a   Suemasu, K ^b   Takei, H ^c   Hozumi, Y ^e   Takehara, M ^e   Saito, T ^d   Ohsumi, S ^f   Masuda, N ^g   Ohashi, Y ^h  

^a Aihara Hospital   (Japan)

^b Arche Clinic   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d SAITAMA RED CROSS HOSPITAL   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION   (Japan)

^g OSAKA NATIONAL HOSPITAL   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anastrozole; Bone mineral density; Bone turnover marker; Early breast cancer; Exemestane

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; BIOLOGICAL MARKER; EXEMESTANE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; FEMALE; HUMAN; JAPAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 79952841608     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323489     Document Type: Article

References (24)

1. Goss PE: Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 2003; 26:S27-S33. (Pubitemid 36966420)
2. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092. (Pubitemid 38298988)
3. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
4. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757. (Pubitemid 43016814)
5. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J: Switching of postmenopausal women with endocrine- responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462. (Pubitemid 41111693)
6. Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H, Iwata H, Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino N, Hisamatsu K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y: Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone- responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat 2010; 121: 379-387.
7. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802. (Pubitemid 37362955)
8. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570.
9. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633-643.
10. Hadji P: Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009; 69: 73-82.
11. Yoneda K, Tanji Y, Okishiro M, Taguchi T, Tamaki Y, Noguchi S: Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference? Ann Oncol 2006; 17: 1175-1176. (Pubitemid 43985259)
12. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-856.
13. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78-84. (Pubitemid 26022463)
14. Deeks ED, Scott LJ: Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs 2009; 69: 889-918.
15. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lonning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE: Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008; 13: 829-837.
16. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J: Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007; 9:R52.
17. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23: 5126-5137. (Pubitemid 46224021)
18. Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA: Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008; 19: 429-435.
19. Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A: Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol 2009; 20: 1203-1209.
20. Jones S, Stokoe C, Sborov M, Braun M, Ethirajan S, Kutteh L, Pippen J, Patel M, Paul D, Blum JL, Holmes FA, Myron MC, Cantrell J, Hartung NL, Look RM, Di Salle E, Davis JC, Ilegbodu D, Asmar L: The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clin Breast Cancer 2008; 8: 527-532.
21. Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A: The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 2009; 18: 159-164.
22. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol 2007; 8: 119-127. (Pubitemid 46158372)
23. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE: Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215-1223. (Pubitemid 44128334)
24. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G: Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J Clin Oncol 2008; 26: 1051-1057.